OncoMatch/Clinical Trials/NCT06066359
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
Is NCT06066359 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies multiple treatments including Fludarabine phosphate and Cyclophosphamide for relapsed/refractory myeloma.
Treatment: Fludarabine phosphate · Cyclophosphamide · Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells — To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Multiple Myeloma
Biomarker criteria
Required: CTAG1B expression (testing required; no eligibility threshold specified)
Required: HLA a*02:01 positive
Required: HLA a*02:05 positive
Required: HLA a*02:06 positive
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: proteasome inhibitor
Must have received: immunomodulatory imide drug
Must have received: anti-cd38 antibody
Lab requirements
Blood counts
anc >= 1000/μl; hemoglobin >= 8 g/dl; platelet count >= 25,000/μl; cytopenias related to myeloma may be permitted if bone marrow plasma cells >= 50%
Kidney function
egfr >= 30 ml/min/1.73 m^2
Liver function
alt/ast <= 2.5 x uln or <= 5 x uln if documented liver metastases; total bilirubin <= 1.5 mg/dl (<= 3.0 mg/dl if gilbert's syndrome); no history of liver cirrhosis; no ascites
Cardiac function
ejection fraction >= 50%; no clinically significant pericardial effusion; no uncontrolled arrhythmias or symptomatic cardiac disease
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06066359 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received proteasome inhibitor and immunomodulatory imide drug.
Does this trial require CTAG1B?
Yes, CTAG1B expression is a required biomarker for enrollment.
Does this trial require HLA?
Yes, HLA a*02:01 positive is a required biomarker for enrollment.
Does this trial require HLA?
Yes, HLA a*02:05 positive is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages